Selected research
Market Structure
Global Plasma-derived Factor VIII Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Plasma-derived Factor VIII market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Plasma-derived Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Plasma-derived Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Plasma-derived Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Plasma-derived Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Plasma-derived Factor VIII include Takeda, RAAS, Hualan Bio, Octapharma, Kedrion, Grifols, Greencross, CSL and BPL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Plasma-derived Factor VIII market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Plasma-derived Factor VIII and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Plasma-derived Factor VIII sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Plasma-derived Factor VIII market size, projected growth trends, production technologies, key applications, and end-use industries.
Plasma-derived Factor VIII Segment by Company
Takeda
RAAS
Hualan Bio
Octapharma
Kedrion
Grifols
Greencross
CSL
BPL
Plasma-derived Factor VIII Segment by Type
200IU
250IU
Plasma-derived Factor VIII Segment by Application
Hospital
Pharmacy
Plasma-derived Factor VIII Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma-derived Factor VIII market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma-derived Factor VIII and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma-derived Factor VIII.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Plasma-derived Factor VIII market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Plasma-derived Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Plasma-derived Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Plasma-derived Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 200IU
- 250IU
Applications
- Hospital
- Pharmacy
Companies covered
- Takeda
- RAAS
- Hualan Bio
- Octapharma
- Kedrion
- Grifols
- Greencross
- CSL
- BPL
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Plasma-derived Factor VIII Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Plasma-derived Factor VIII Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Plasma-derived Factor VIII Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Plasma-derived Factor VIII Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Plasma-derived Factor VIII Market Dynamics
- 2.1 Plasma-derived Factor VIII Industry Trends
- 2.2 Plasma-derived Factor VIII Industry Drivers
- 2.3 Plasma-derived Factor VIII Industry Opportunities and Challenges
- 2.4 Plasma-derived Factor VIII Industry Restraints
3 Plasma-derived Factor VIII Market by Manufacturers
- 3.1 Global Plasma-derived Factor VIII Revenue by Manufacturers (2021-2026)
- 3.2 Global Plasma-derived Factor VIII Sales by Manufacturers (2021-2026)
- 3.3 Global Plasma-derived Factor VIII Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Plasma-derived Factor VIII Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Plasma-derived Factor VIII Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Plasma-derived Factor VIII Manufacturers, Product Type & Application
- 3.7 Global Plasma-derived Factor VIII Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Plasma-derived Factor VIII Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Plasma-derived Factor VIII Players Market Share by Revenue in 2025
- 3.8.3 2025 Plasma-derived Factor VIII Tier 1, Tier 2, and Tier 3
4 Plasma-derived Factor VIII Market by Type
- 4.1 Plasma-derived Factor VIII Type Introduction
- 4.1.1 200IU
- 4.1.2 250IU
- 4.2 Global Plasma-derived Factor VIII Sales by Type
- 4.2.1 Global Plasma-derived Factor VIII Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Plasma-derived Factor VIII Sales by Type (2021-2032)
- 4.2.3 Global Plasma-derived Factor VIII Sales Market Share by Type (2021-2032)
- 4.3 Global Plasma-derived Factor VIII Revenue by Type
- 4.3.1 Global Plasma-derived Factor VIII Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Plasma-derived Factor VIII Revenue by Type (2021-2032)
- 4.3.3 Global Plasma-derived Factor VIII Revenue Market Share by Type (2021-2032)
5 Plasma-derived Factor VIII Market by Application
- 5.1 Plasma-derived Factor VIII Application Introduction
- 5.1.1 Hospital
- 5.1.2 Pharmacy
- 5.2 Global Plasma-derived Factor VIII Sales by Application
- 5.2.1 Global Plasma-derived Factor VIII Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Plasma-derived Factor VIII Sales by Application (2021-2032)
- 5.2.3 Global Plasma-derived Factor VIII Sales Market Share by Application (2021-2032)
- 5.3 Global Plasma-derived Factor VIII Revenue by Application
- 5.3.1 Global Plasma-derived Factor VIII Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Plasma-derived Factor VIII Revenue by Application (2021-2032)
- 5.3.3 Global Plasma-derived Factor VIII Revenue Market Share by Application (2021-2032)
6 Global Plasma-derived Factor VIII Sales by Region
- 6.1 Global Plasma-derived Factor VIII Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Plasma-derived Factor VIII Sales by Region (2021-2032)
- 6.2.1 Global Plasma-derived Factor VIII Sales by Region (2021-2026)
- 6.2.2 Global Plasma-derived Factor VIII Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Plasma-derived Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Plasma-derived Factor VIII Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Plasma-derived Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Plasma-derived Factor VIII Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Plasma-derived Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Plasma-derived Factor VIII Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Plasma-derived Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Plasma-derived Factor VIII Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Plasma-derived Factor VIII Revenue by Region
- 7.1 Global Plasma-derived Factor VIII Revenue by Region
- 7.1.1 Global Plasma-derived Factor VIII Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Plasma-derived Factor VIII Revenue by Region (2021-2026)
- 7.1.3 Global Plasma-derived Factor VIII Revenue by Region (2027-2032)
- 7.1.4 Global Plasma-derived Factor VIII Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Plasma-derived Factor VIII Revenue (2021-2032)
- 7.2.2 North America Plasma-derived Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Plasma-derived Factor VIII Revenue (2021-2032)
- 7.3.2 Europe Plasma-derived Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Plasma-derived Factor VIII Revenue (2021-2032)
- 7.4.2 Asia-Pacific Plasma-derived Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Plasma-derived Factor VIII Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Plasma-derived Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Plasma-derived Factor VIII Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 RAAS
- 8.2.1 RAAS Company Information
- 8.2.2 RAAS Business Overview
- 8.2.3 RAAS Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 RAAS Plasma-derived Factor VIII Product Portfolio
- 8.2.5 RAAS Recent Developments
- 8.3 Hualan Bio
- 8.3.1 Hualan Bio Company Information
- 8.3.2 Hualan Bio Business Overview
- 8.3.3 Hualan Bio Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Hualan Bio Plasma-derived Factor VIII Product Portfolio
- 8.3.5 Hualan Bio Recent Developments
- 8.4 Octapharma
- 8.4.1 Octapharma Company Information
- 8.4.2 Octapharma Business Overview
- 8.4.3 Octapharma Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Octapharma Plasma-derived Factor VIII Product Portfolio
- 8.4.5 Octapharma Recent Developments
- 8.5 Kedrion
- 8.5.1 Kedrion Company Information
- 8.5.2 Kedrion Business Overview
- 8.5.3 Kedrion Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Kedrion Plasma-derived Factor VIII Product Portfolio
- 8.5.5 Kedrion Recent Developments
- 8.6 Grifols
- 8.6.1 Grifols Company Information
- 8.6.2 Grifols Business Overview
- 8.6.3 Grifols Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Grifols Plasma-derived Factor VIII Product Portfolio
- 8.6.5 Grifols Recent Developments
- 8.7 Greencross
- 8.7.1 Greencross Company Information
- 8.7.2 Greencross Business Overview
- 8.7.3 Greencross Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Greencross Plasma-derived Factor VIII Product Portfolio
- 8.7.5 Greencross Recent Developments
- 8.8 CSL
- 8.8.1 CSL Company Information
- 8.8.2 CSL Business Overview
- 8.8.3 CSL Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 CSL Plasma-derived Factor VIII Product Portfolio
- 8.8.5 CSL Recent Developments
- 8.9 BPL
- 8.9.1 BPL Company Information
- 8.9.2 BPL Business Overview
- 8.9.3 BPL Plasma-derived Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 BPL Plasma-derived Factor VIII Product Portfolio
- 8.9.5 BPL Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Plasma-derived Factor VIII Value Chain Analysis
- 9.1.1 Plasma-derived Factor VIII Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Plasma-derived Factor VIII Production Mode & Process
- 9.2 Plasma-derived Factor VIII Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Plasma-derived Factor VIII Distributors
- 9.2.3 Plasma-derived Factor VIII Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst